News | July 06, 2022
Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Medicines, including insulin, to be available in 40 lower-income countries
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Bringing next-gen cannabinoid therapeutics to cancer patients
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Subscribe To Our Newsletter & Stay Updated
